Clinical trials: Alzheimer Disease (AD)
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer's Disease
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Recent data show that marked cell damage precedes the clinical manifestation of Alzheimer's disease (AD). Hence, targeting populations at risk with pharmacological interventions is a possible strategy to lessen the burden of the…
- Trial name
- NCT00933608
- Testing
- memantine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer Disease, Mild Memory Disturbance
The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study
The purpose of this research study is to learn whether it is possible and useful for caregivers to report behavioral or psychological symptoms of people with mild memory problems or Alzheimer's disease through a smartphone mobile…
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Trial name
- MOMENT (NCT04482036)
- Testing
- Mobile Phone Application Assessments, Standard Assessments
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease (AD)
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).
- Trial name
- TOAD (NCT02593318)
- Testing
- Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Russell Swerdlow
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Alzheimer Disease
A Dyadic Approach for a Remote Physical Activity Intervention in Adults With AD and Their Caregivers
The objective of this study is to compare the effectiveness of 2 intervention delivery strategies for increasing moderate physical activity (MPA), real-time group video conferencing (RGV) vs.
- Trial name
- NCT04102514
- Testing
- Real-time Group Video, Enhanced Usual Care
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of Kansas
Alzheimer's Disease
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
- Trial name
- DISCOVER (NCT02925650)
- Testing
- Posiphen
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Annovis Bio Inc.
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
The purpose of this study is to determine whether alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease compared…
- Trial name
- TEAM-AD (NCT00235716)
- Testing
- dl-alpha-tocopherol, Memantine
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 613 people
- Sponsor
- US Department of Veterans Affairs
Alzheimer's Disease
Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
The purpose of this study is to investigate the effect of the rapidly acting intranasal insulin derivative (glulisine) on memory and cognition in 12 patients suffering from mild-moderate Alzheimer's Disease (AD) using a…
- Trial name
- NCT01436045
- Testing
- Insulin glulisine, Saline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- HealthPartners Institute
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can arrest or reverse the disease at its earliest stages.
- Trial name
- NCT01767909
- Testing
- Insulin (Humulin® R U-100)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- University of Southern California
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Alzheimer Disease, Mild Cognitive Impairment
Brain Energy for Amyloid Transformation in Alzheimer's Disease Study
The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment.
- Trial name
- BEAT-AD (NCT03472664)
- Testing
- low carbohydrate/high fat diet, low fat/high carbohydrate diet
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Wake Forest University Health Sciences
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease.
- Trial name
- NCT02503501
- Testing
- Insulin glulisine
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- HealthPartners Institute
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
This study aims to determine whether the Cogstate testing battery can detect improvements in cognitive function in participants with mild AD.
- Trial name
- NCT02064920
- Testing
- Donepezil
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC